Verastem
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 73
- Market Cap
- -
- Website
- http://www.verastem.com
- Introduction
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
Clinical Trials
60
Trial Phases
3 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (56 trials with phase data)• Click on a phase to view related trials
A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Conditions
- Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal CancerSolid Tumor, AdultG12D Mutated KRAS
- Interventions
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT07020221
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
- Conditions
- Low Grade Serous Ovarian CancerOvarian Cancer
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06682572
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵Kurume University Hospital, Kurume, Fukuoka, Japan
🇯🇵Mie University Hospital, Tsu, Mie, Japan
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Conditions
- Low Grade Serous Ovarian Cancer
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06072781
- Locations
- 🇺🇸
HonorHealth, Phoenix, Arizona, United States
🇺🇸University of Arkansas, Little Rock, Arkansas, United States
🇺🇸UCLA Health, Los Angeles, California, United States
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
- Conditions
- Metastatic CancerPancreas CancerNeoplasms PancreaticMalignant Neoplasm of PancreasKRAS Activating Mutation
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05669482
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
- Conditions
- Non Small Cell Lung CancerKRAS Activating MutationAdvanced CancerMetastatic CancerMalignant Neoplastic DiseaseMalignant Neoplasm of Lung
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT05375994
- Locations
- 🇺🇸
UCSF Thoracic Oncology, San Francisco, California, United States
🇺🇸University of Colorado Hospital Anschutz Cancer Pavllion, Aurora, Colorado, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next